Patents by Inventor Takashi SHIRAKURA
Takashi SHIRAKURA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190374515Abstract: The present invention pertains to a therapeutic drug or prophylactic drug for diabetic nephropathy, said drug comprising a compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.Type: ApplicationFiled: November 27, 2017Publication date: December 12, 2019Applicant: TEIJIN PHARMA LIMITEDInventors: Takashi SHIRAKURA, Shunsuke TSUJIMOTO, Yoshiki TSUBOSAKA
-
Patent number: 10301300Abstract: Provided are a xanthine oxidase inhibitor, a drug for improving vascular endothelial function, and an excellent therapeutic or prophylactic drug for diseases associated with xanthine oxidase such as gout, hyperuricaemia, and for diseases associated with vascular endothelial functional disorder containing a compound represented in a formula (I) or the pharmaceutically acceptable salt thereof as an active ingredient.Type: GrantFiled: May 1, 2018Date of Patent: May 28, 2019Assignee: TEIJIN LIMITEDInventors: Takashi Shirakura, Yoshimasa Takahashi, Asahi Kawana, Chikashi Kanazawa
-
Publication number: 20180244665Abstract: Provided are a xanthine oxidase inhibitor, a drug for improving vascular endothelial function, and an excellent therapeutic or prophylactic drug for diseases associated with xanthine oxidase such as gout, hyperuricaemia, and for diseases associated with vascular endothelial functional disorder containing a compound represented in a formula (I) or the pharmaceutically acceptable salt thereof as an active ingredient.Type: ApplicationFiled: May 1, 2018Publication date: August 30, 2018Applicant: Teijin Pharma LimitedInventors: Takashi SHIRAKURA, Yoshimasa TAKAHASHI, Asahi KAWANA, Chikashi KANAZAWA
-
Publication number: 20170217948Abstract: Provided are a xanthine oxidase inhibitor, a drug for improving vascular endothelial function, and an excellent therapeutic or prophylactic drug for diseases associated with xanthine oxidase such as gout, hyperuricaemia, and for diseases associated with vascular endothelial functional disorder containing a compound represented in a formula (I) or the pharmaceutically acceptable salt thereof as an active ingredient.Type: ApplicationFiled: July 29, 2015Publication date: August 3, 2017Applicant: Teijin Pharma LimitedInventors: Takashi SHIRAKURA, Yoshimasa TAKAHASHI, Asahi KAWANA, Chikashi KANAZAWA
-
Patent number: 9545445Abstract: The present invention relates to a therapeutic drug or a preventive drug for hypertension or high-normal blood pressure, comprising (a) and (b) as active ingredients: (a) a 2-phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof; (b) at least one compound or a pharmaceutically acceptable salt thereof selected from the group consisting of calcium antagonists, renin-angiotensin system inhibitors, diuretics, sympatholytic agents, vasodilators, and medicinally acceptable salts of these. The present invention also relates to a therapeutic method or a preventive method for hypertension or high-normal blood pressure, comprising administering the above (a) and (b) in amounts effective for treating or preventing hypertension or high-normal blood pressure.Type: GrantFiled: June 25, 2010Date of Patent: January 17, 2017Assignee: Teijin Pharma LimitedInventors: Takashi Shirakura, Mizuho Tamura, Yoshimasa Takahashi, Ippei Kuwahara
-
Patent number: 9388174Abstract: The present invention provides: a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which has an excellent inhibitory activity on xanthine oxidase and is useful as a therapeutic agent or a prophylactic agent for diseases associated with xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stone, hypertension, dyslipidemia, diabetes, cardiovascular diseases including arteriosclerosis and heart failure, renal diseases including diabetic nephropathy, respiratory diseases including chronic obstructive pulmonary disease, inflammatory bowel disease or autoimmune diseases; and a medicine or a pharmaceutical composition comprising the compound or the salt as an active ingredient.Type: GrantFiled: January 30, 2014Date of Patent: July 12, 2016Assignee: Teijin Pharma LimitedInventors: Asahi Kawana, Chikashi Kanazawa, Yoshimasa Takahashi, Takashi Shirakura
-
Publication number: 20150376174Abstract: The present invention provides: a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, which has an excellent inhibitory activity on xanthine oxidase and is useful as a therapeutic agent or a prophylactic agent for diseases associated with xanthine oxidase, such as gout, hyperuricemia, tumor lysis syndrome, urinary tract stone, hypertension, dyslipidemia, diabetes, cardiovascular diseases including arteriosclerosis and heart failure, renal diseases including diabetic nephropathy, respiratory diseases including chronic obstructive pulmonary disease, inflammatory bowel disease or autoimmune diseases; and a medicine or a pharmaceutical composition comprising the compound or the salt as an active ingredient.Type: ApplicationFiled: January 30, 2014Publication date: December 31, 2015Applicant: TEIJIN PHARMA LIMITEDInventors: Asahi KAWANA, Chikashi KANAZAWA, Yoshimasa TAKAHASHI, Takashi SHIRAKURA
-
Publication number: 20150005506Abstract: The purpose of the present invention is to provide a novel therapeutic agent or a novel prophylactic agent for diseases associated with abnormal glucose metabolism. The present invention is a therapeutic agent or a prophylactic agent for diseases associated with abnormal glucose metabolism, which comprises a 2-phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient.Type: ApplicationFiled: January 25, 2013Publication date: January 1, 2015Applicants: NATIONAL UNIVERSITY CORPORATION TOTTORI UNIVERSITY, TEIJIN PHARMA LIMITEDInventors: Ichiro Hisatome, Shunsuke Tsujimoto, Takashi Shirakura, Shinya Hiramitsu
-
Publication number: 20130109726Abstract: The present invention provides a therapeutic or preventive agent for hypertension or normal high blood pressure, and for renal dysfunction, that is more effective than existing drugs. More specifically, the present invention provides a sustained-release pharmaceutical composition for treating or preventing hypertension or normal high blood pressure, and for renal dysfunction, comprising as an active ingredient a 2-phenylthiazole compound represented by the following formula (I) or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 24, 2011Publication date: May 2, 2013Applicant: TEIJIN PHARMA LIMITEDInventors: Takashi Shirakura, Mizuho Tamura, Yoshimasa Takahashi, Ippei Kuwahara
-
Publication number: 20110046192Abstract: The present invention relates to a therapeutic drug or a preventive drug for hypertension or high-normal blood pressure, comprising (a) and (b) as active ingredients: (a) a 2-phenylthiazole compound represented by formula (I) or a pharmaceutically acceptable salt thereof; (b) at least one compound or a pharmaceutically acceptable salt thereof selected from the group consisting of calcium antagonists, renin-angiotensin system inhibitors, diuretics, sympatholytic agents, vasodilators, and medicinally acceptable salts of these. The present invention also relates to a therapeutic method or a preventive method for hypertension or high-normal blood pressure, comprising administering the above (a) and (b) in amounts effective for treating or preventing hypertension or high-normal blood pressure.Type: ApplicationFiled: June 25, 2010Publication date: February 24, 2011Applicant: Teijin Pharma LimitedInventors: Takashi SHIRAKURA, Mizuho Tamura, Yoshimasa Takahashi, Ippei Kuwahara